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Ankylosing spondylitis (AS)' is an inflammatory disease ofunknown etiology, affect-
ing the sacroiliacjoints, spine, and peripheraljoints . Patientsmay also developocular
inflammation, such as acute anterior uveitis . More than 90% of Caucasian patients
with AS carry the MHC class I gene, HLA B27, whereas the frequency ofHLA
B27 in the generalCaucasian population is<10% . One ofthe hypotheses postulated
to explain this association and the possible aetiology ofAS is the concept of molec-
ular mimicry, i.e., that there is immunological crossreactivity between antigens on
bacteria and the HLA B27 molecule (1) .
The first indirect evidence of this crossreactivity came from the work of Ebringer
and colleagues in 1976 (2), who showed that antisera from rabbits immunized with
HLA B27+ human lymphocytes reacted with Klebsiella aerogenes . These results sug-
gested that there was partial crossreactivity between some antigens present onHLA
B27 lymphocytes, possibly HLA B27 itself, and antigenic components on Klebsiella .
Subsequent studies showed that Klebsiella pneumoniae is carried more frequently in
the feces ofAS patients with active disease (3, 4), and in patients with acute anterior
uveitis (5, 6) . Similarly, patients classified as having active disease and erythrocyte
sedimentation rates of >15 mm/h were shown to have elevated levels of IgA anti-
bodies to Klebsiella in their sera, compared with sera ofpatients with inactive disease
and sera from healthy control subjects (7, 8) .
More recent confirmations ofthis immunological crossreactivity have been demon-
strated by Ogawasara and colleagues (9) with an anti-HLA B27 mAb reactive against
60,000 and 80,000 dalton antigens on Klebsiella pneumoniae and not with other Gram-
negative bacteria . The 80,000 dalton molecule was purified and used to immunize
guinea pigs . The guinea pig sera showed reduced antibody activity to Klebsiella enve-
lopes when adsorbed with HLA B27+ cells . It has now been shown that there is a
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consecutive sequence of six amino acids, GlnThr-Asp-Arg-Glu-Asp (QTDRED)
shared between HLA B27 .1 and the nitrogenase reductase enzyme of Klebsiella pneu-
moniae (10). This sequence homology has provided a possible structural basis for cross-
reactivity to occur. The resolution of the three-dimensional structure of the HLA
class I antigen HLA A2 revealed that the area of sequence homology occurs on the
surface of the al domain, in the hypervariable region of MHC class I molecules
(11, 12) . It has also been shown that sera from patients with AS or Reiter's syndrome
contain antibodies that react with synthetic peptides containing the homologous se-
quence that is shared by HLA B27 .1 and Klebsiella pneumoniae nitrogenase reductase
(10). 29% of sera from AS patients had antibody activity to a peptide of 16 amino
acids from HLA B27.1 (residues 69-84), whereas none of the HLA B27+ healthy
individuals (n = 22) had this antibody activity. Greater than 40% ofthe AS patient
sera had antibodies to a synthetic peptide of 13 amino acids from Klebsiella pneumo-
niae nitrogenase (residues 184-196). One of the 90 healthy controls (non-HLA-matched
had antibody activity to the Klebsiella peptide.
In the study reported here, overlapping peptides from the regions of interest were
systematically synthesized and tested with a series of HLA-typed sera from AS pa-
tients and healthy controls to confirm the presence of antibody activity to Klebsiella
and HLA B27 peptides in AS patient sera and to delineate the putative crossreactive
epitopes with greater precision.
Materials and Methods
Patients and Control Sera.
￿
Fifty patients fulfilling the New York criteria for AS were exam-
ined and bled in the Rheumatology Clinic of the Department of Medicine, University of'
Melbourne, Austin Hospital. The patients were tissue typed at the Royal Melbourne Hos-
pital tissue typing laboratory, by Dr. Brian Tait. Sera were aliquoted and stored at -20°C.
Family studies of AS patients had previously identified healthy first-degree relatives with no
history or clinical signsofAS. These relatives were tissue typed and theirsera stored at -20°C.
Twenty-two HLA B27' and 22 HLA B27 - sera were randomly chosen from these first-degree
relatives as control sera.
PeptideSynthesis.
￿
Peptides were synthesized at Coselco Mimotopes Pty. Ltd., Parkville, Aus-
tralia. Peptides were synthesized on solid polyethylene rods using the method of Geysen (13).
Measurement ofAntibody Activity to Peptides by ELISA.
￿
Assemblies of 96 polyethylene rods
with the peptides covalently attached were arranged on supports in a configuration that al-
lowed the rods to be inserted into the wells of a microtiter tray. The rod-coupled peptides
were precoated with 2olo BSA (Commonwealth Serum Laboratories, Parkville, Australia) and
0.10 1o Tween 20 (vol/vol) in PBS, pH 7 .4, for 1 h at 20°C. Dilutions of sera at 1/2,000 in PBS
containing 2% BSA (wt/vol), 0.1% Tween 20 (vol/vol), and 0.2% sodium azide (wt/vol) were
prepared, and 175 Etl was added to appropriate wells of microtiter plates. The precoated pep-
tides on the rods were incubated with the diluted sera overnight at 4°C. The rods were then
washed four times for 10 min by immersing the rods in a shaking bath containing PBS. The
rods were then incubated with enzyme conjugate, goat anti-human IgG + IgA + IgM (heavy
+ light chains), coupled to horse radish peroxidase (Kirkegaard and Perry Laboratories,
Gaithersburg, MD), diluted to 1/2,000 in PBS containing 0.1% (wt/vol) sodium caseinate
(United States Biochemical Co., Cleveland, OH) and 1% (vol/vol) normal sheep serum for
1 h at 20°C . After washing, the rods were incubated with the substrate H202 (0.01% vol/vol)
and 2,2'-azino-di-(-3-ethyl-benzthiazolinesulfonic acid) 0 .09 mM (Boehringer-Mannheim,
Federal Republic of Germany) in 80 mM citric acid/100 mM phosphate buffer (pH 4.0). The
absorbance at 405 nm was read after45 min in a Titertek Multiskan MC (FlowLaboratories,
McLean, VA) .Results
Testing ofAmino Acid Octamersfrom Klebsiella and HLA B27.
￿
All possible overlap-
ping peptides ofeight amino acids from Klebsiella pneumoniae nitrogenase reductase
(residues 181-199) and HLA B27.1 (residues 65-85) were synthesized onto polyeth-
ylene rods, with eight rods of each peptide being made. AS patient sera selected
on the basis ofelevated erythrocyte sedimentation rate (ESR >15 mm/h), and sera
from HLA B27+ healthy individuals, were tested. Each serum was tested in dupli-
cate. Fig. 1 shows the activity ofone AS patient serum and two control sera against
overlappingKlebsiella peptides ofeight aminoacids. Patient237 serum hadmaximal
antibody activity against peptides ICNSRQTD (residues 183-190) and CNSRQTDR
(residues 184-191). By contrast, the two B27+ control sera showed minimal binding
activity against all peptides. Fig. 2 shows the same patient serum and control sera
reacting with overlapping peptides ofeight amino acids synthesized from the HLA
B27.1 molecule. The patient serum showed antibody activity against two regions
in the sequence spanning residues 65-85. The most reactive peptides were CKA-
KAQTD (residues 67-74), KAKAQI'DR (residues 68-75), and REDLRTLL
(residues 75-82). The control sera showed minimal binding to the peptides. It is
ofnote that octapeptides containing the entire homologous sequence (QTDRED)
did nothave ahigh reactivity againstthe patientserum. Adding furtheramino acids
of the sequence to QTDR in the direction of the COON terminus (or removal of
amino acids from the NH2 terminus) reduced the reactivity ofthe serum against
the peptide markedly. Figs. 3 and 4 show a further set offour patient sera reacting
with the same Klebsiella and HLA B27.1 amino acid octamers, as shown in Figs.
1 and 2. All five AS sera selected gave similar antibody binding profiles against the
peptides, and confirmed the presence of two reactive sites within the HLA B27.1
sequence tested. Both these regions included part, but not all, ofthe homologous
sequence QTDRED. Similarly, the most reactive Klebsiella peptides contained the
amino acids QTD or QTDR from the homologous sequence.
TestingASSera with DifferentLength Peptidesfrom Klebsiella andHLA B27
￿
In seeking
to delineate the putative crossreactive epitopes further, overlapping peptides ranging
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FIGURE 1. Serum from one HLA
B27' ankylosing spondylitis (AS) pa-
tient and two healthy B27' controls
reacting with overlapping synthetic
peptides of eight amino acids from
K pneumoniae nitrogenase reductase (se-
quence 181-199) by ELISA. The pep-
tides tested are shown along the
horizontal axis. They-axis shows ab-
sorbance at 405 nm. Sera were tested
at dilutions of 1/2,000. Dotted squares
show the antibody activity in the pa-
tient serum with 14 overlapping pep-
tides. The filled squares and filled dia-
monds represent antibody activity in
sera from two 1127' healthy controls.1638
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FIGURE 2. Serum from one HLA
B27' AS patient and twohealthy B27'
controls reactingwith overlapping syn-
thetic peptides of eight amino acids
from the HLA B27.1 (sequence 65-85)
by ELISA. Peptides tested are shown
along the horizontal axis. They-axis
shows absorbance at 405 nm. The sera
were tested at dilutions of 1/2,000.
Dotted squares show the antibody ac-
tivity in the patient serum with 12 over-
lapping peptides. Filled squares and
filled diamonds represent antibody ac-
tivity in the sera of the two healthy
B27' controls against the same pep-
tides.
FIGURE 3.
￿
Four AS patient sera reacting
with overlapping synthetic peptides of 8
amino acids from K. pneumoniae nitro-
genase reductase (sequence 181-199) by
ELISA. Peptides tested are shown along
the horizontal axis. They-axis shows ab-
sorbance at 405 rim. Sera were tested at
dilutions of 1/2,000. Dotted squares rep-
resent patient 68, filled diamonds repre-
sent patient 436, filled squares represent
patient 224, andopen diamonds represent
patient 209.
from 4- and 8-amino acids, derived from K. pneumoniae nitrogenase (183-193) and
HLA B27.1 (67-77) were synthesized on polyethylene rods and tested with four AS
patient sera. Table I shows the strategy of the peptides synthesized.
This strategy of synthesis allowed us to determine the optimum and minimum
sequence to which antibodies in AS sera can bind. Fig. 5 shows the cumulative data
from the testing ofthese peptides (not all data shown). The three most reactive pep-
tides were RQTDR (Klebsiella), NSRQTDR (Klebsiella), and KAKAQTDR (HLA
B27.1). Thus RQTDR, a 5-mer derived from Klebsiella is able to form a sequential
epitope. The 7-mer NSRQTDR was comparably reactive against AS patient sera.
It is likely that this epitope identified on Klebsiella nitrogenase comprises more than
one overlapping epitope, with the boundaries of the epitope being 183ICNSRQ-
TDRt9t. The sequence for optimum antibody binding in the HLA B27 .1 set of pep-
tides was KAKAQTDR. Shorter peptides about this region gave comparable binding
against AS sera. This region is likely to comprise more than one overlapping epi-
tope, the boundaries of this epitope being 67CKAKAQTDR75.
The above data showed that QTDR appears to be an important sequence for anti-
body binding, but this peptide of four amino acids alone had little reactivity againstE L
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FIGURE 4 .
￿
Four AS patient sera re-
acting with overlapping synthetic pep-
tides ofeight amino acids from HLA
B27 .1 (sequence 65-85) by ELISA .
Peptides tested are shown along the
horizontal axis . They-axis shows ab-
sorbance at 405 nm . Sera were tested
at dilutions of 1/2,000. Dotted squares
represent patient 68, filled diamonds
represent patient 436, filled squares
represent patient 224, and open dia-
monds represent patient 209 .
AS patient sera. Also, the peptideQTDREDwasnot highly reactive against patient
sera .
Based on the above results of testing peptides of different lengths, the three most
reactive peptides were synthesized on polyethylene rods . A bank of sera from AS
patients and sera from healthy B27' and B27 - individuals who were first-degree
relatives ofAS patients were tested simultaneously byELISA against thesepeptides .
Each serum was tested with each peptide in quadruplicate.
Figs . 6-8 show the data for 50 AS patient sera, 22 HLA B27 + control sera, and
22 HLA B27 - control sera, binding to peptides RQTDR, NSRQTDR, and KAK-
AQTDR, respectively . The overlap in antibody activity in patient sera and control
TABLE 1
Synthesis Strategy of Peptides of Four to Eight Amino Acidsfrom
Klebsiella pneumoniae Nitrogenase Reductase and HLA B27.1
Starting residue no . 4-mers 5-mers 6-mers 7-mers 8-mers
Klebsiella pneumoniae nitrogenase reductase sequences
183 ICNSRQTD
184 CNSRQTD CNSRQTDR
185 NSRQTD NSRQTDR NSRQTDRE
186 SRQTD SRQTDR SRQTDRE SRQTDRED
187 RQTD RQTDR RQTDRE RQTDRED
188 QTDR QTDRE QTDRED
189 TDRE TDRED
190 DRED
HLA B27 .1 sequences
67 CKAKAQTD
68 KAKAQTD KAKAQTDR
69 AKAQTD AKAQTDR AKAQTDRE
70 KAQTD KAQTDR KAQTDRE KAQTDRED
71 AQTD AQTDR AQTDRE AQTDRED
72 QTDR QTDRE QTDRED
73 TDRE TDRED
74 DRED1640
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FIGURE 5 . Four AS patient
sera (average absorbance value)
reacting with overlapping pep-
tides from K pneumoniae nitro-
genase reductase synthetic pep-
tides (sequence 183-193) and
HLA B27 .1 synthetic peptides
(sequence 67-77), of four to
eight amino acids by ELISA .
Peptides are shown along the
horizontal axis (all results not
shown). They-axis showsabsor-
bance at 405 nm . Sera were
tested at dilutions of 1/2,000 .
sera wasconsiderable, but for reactivity against KAKAQTDR, . themean absorbance
value of 50 patient sera was statistically significantly greater than the mean absor-
bance of either control group sera, using the Student's t-test (p < 0.001) . For binding
to NSRQTDR, the mean absorbance value for50 patient sera was significantly greater
FIGURE 6 .
￿
50 HLA B27' AS patient sera
(0), 22 HLA B27' healthy control sera (O),
and 22 HLA B27- healthy control sera (O)
reacting with K pneumoniae nitrogenase reduc-
tase synthetic peptide RQTDR (residues
187-191) by ELISA. They-axis shows absor-
bance at 405nm . Sera were tested at dilutions
of 1/2,000 . SEM is shown next to each group
of sera.EWING ET AL.
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AS patients
￿
Controls
￿
Controls
n=50 827(+) B27H
n=22 n=22
FIGURE 7.
￿
50 HLA B27' AS patient sera ( "),
22 HLA B27' healthy control sera (O), and 22
HLA B27 - healthy control sera (O) reacting
with K. pneumoniae nitrogenase reductase synthetic
peptide NSRQTDR (residues 185-191) by
ELISA. They-axis shows absorbance at 405 nm.
Sera were tested at dilutions of 1/2,000. SEM is
shown next to each group of sera.
than that of the B27- control group (p <0.002). There was a less significant differ-
ence between the patient group and the B27 + control group (p <0.02). Although
differences wereobserved betweenpatient and controlgroups with bindingtoRQTDR,
these were not statistically significant (p <0.07). In all these ELISA assays there were
no significant differences between the mean absorbance values ofthe B27' and B27-
control group sera.
Comparison of Antibody Activity Against NSRQTDR and KAKAQTDR in AS Patient
Sera. Antibody activity against the HLA B27.1 peptide KAKAQTDR was plotted
against antibody activity tothe Klebsiella peptide NSRQTDR for the 50 patient sera
tested, shown in Fig. 9. AS patient sera that showed high antibody bindingactivity
against NSRQTDR also showed high binding against KAKAQTDR (r = 0.90,
p < 0.001).
Discussion
Molecular mimicry is defined as the sharing ofepitopes from disparate proteins,
and sharing of epitopes may be an important phenomenon in the pathogenesis of
ankylosing spondylitis. Antibodies made to bacteria like Klebsiella may crossreact
with HLA B27, thereby mimicking an autoimmune reaction.
Ourstudies have shown that there are antibodies in AS sera which bind to K. pneu-
moniae nitrogenase reductase and HLA B27.1 peptides. In the initial studies with
overlappingoctapeptides, five AS sera showed maximal antibody binding to IONS-
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FIGURE 8 . 50 HLA B27' AS patient sera
(" ), 22 HLA B27' healthy control sera (O),
and 22 HLA B27- healthy control sera (O)
reacting with HLA B27 .1 synthetic peptide
KAKAQTDR (residues 68-75) by ELISA .
They-axis shows absorbance at 405 nm. Sera
were tested at dilutions of 1/2,000 . SEM is
shown next to each group of sera .
AS patients
￿
Controls
￿
Controls
n=50 B27(*) B27(-)
n=22 n=22
RQTD (residues 183-190) and CNSRQTDR (residues 184-191) . The sera showed
relatively low antibody activity against octapeptides that included the entire homol-
ogous sequence QTDRED. In fact, the sera showed markedly diminished activity
against reptides with ED (Glu-Asp) added on in the direction of the COOH ter-
minus . Our data show thatQTDR appear to be the important residues (of the ho-
mologous sequence) ofK. pneumoniae nitrogenase for antibody binding. In our studies
with overlapping peptides ofvarying lengths from four to eight amino acids derived
from K. pneumoniae nitrogenase, AS sera showed the highest antibody activity against
FIGURE 9 .
￿
Simple regression plot of 50 AS
sera reacting with HLA B27 .1 8-mer KAK-
AQTDR versus 50 AS patient sera reacting
withK . pneumoniae 7-merNSRQTDR . Values
plotted on both the y- and x-axes are absor-
bances at 405 nm . Correlation coefficient =
0.90, p < 0.001 .
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RQTDR and NSRQTDR. Although we had identified QTDR as being important
residues, 4-mers ofQTDR showed little reactivity against AS sera. Our conclusion
is that there are overlapping epitopes identified by AS sera on K. pneumoniae offive
to eight amino acids contained within the sequence 1831CNSRQTDR'91. The
boundary ofthis epitope in theCOOH-terminal direction is arginine (residue 191).
In studies with overlapping octapeptides from HLA B27.1, two distinct regions
within the sequence 65-85 were identified as being reactive against AS sera. The
region thatwehavenamedepitopeIis represented by KAKAQTDR (residues68-75).
The second region, which similarly included part, but not all, of the homologous
sequence was the peptide REDLRTLL. We have provisionally named this region
epitope II. Octapeptides from HLA B27.1 that included the entire homologous se-
quence were again weakly reactive. Synthesis and systematic testing ofoverlapping
peptides from four to eight amino acids in the region of epitope I demonstrated
that KAKAQTDR was the most reactive peptide. Epitope I is likely to comprise
several overlapping peptides, the boundaries ofthe epitope being 67CKAKAQTDR75.
Other studies have shown that an epitope recognized by polyclonal antiserais likely
to be comprised ofseveral overlapping epitopes (14). Epitope II on HLA B27.1 has
not yet been mapped in detail to determine the minimal and optimal peptide to
which antibodies in AS sera bind. However, it also corresponds to an epitope recog-
nizedbymouse(anti-Klebsiella) serum(Ewing, C.M.,et al.,manuscript inpreparation).
The results of these systematic studies with Klebsiella and HLA B27.1 peptides
have given specific definition to the peptides that may form the putative crossreac-
tive epitopes. The data suggest that QTDRED itself is not the crossreactive anti-
genic determinant, but that peptides containing part ofthis sequence (QTDR) are
responsible for the initial antibody response to Klebsiella and subsequent crossreac-
tivity with HLA B27. Data obtained by Schwimmbeck and Oldstone (15) showed
that antisera raised in rabbits and rats to peptides derived from HLA B27.1 (69-84)
reacted with the peptide used for immunization but also with a K. pneumoniae
nitrogenase peptide (185-196). A shorter peptide derived from HLA B27.1 (69-78)
containing the homologous sequence also reactedwiththe antisera. Theyconcluded
that theantigenic determinant is identicalto the linear six amino acidsequence shared
by HLA B27.1 and K. pneumoniae nitrogenase. Ourdatahave more precisely identified
the epitopes using human AS sera, and moreover we have shown that there are at
least two distinct autoantigenic determinants on HLA B27.1. Our results, however,
do not preclude that antibodies in AS patient sera can bind to longer peptide se-
quencesthat includeone orboth ofthese HLA B27 epitopes. Crossreaction ofanti-
genic determinants in vivo means that antibodies to short Klebsiella peptides must
necessarilybind to thenative HLAB27 moleculeto induce "autoimmunity."Indeed,
it has also recently been shown that antibodies to peptide sequences derived from
K. pneumoniae and HLA B27.1 that contain thehomologous sequence bind to syno-
vial tissue from patients with AS and Reiter's syndrome (16).
Not all subtypes ofHLAB27 contain the sequencesQTDRED. Substitutionsoccur
at position 77. It has been shown that antisera raised in rabbits to HLA B27.1 pep-
tide69-84, which includes the homologous sequence, can discriminate between the
subtypes ofHLA B27 in cytotoxicityassays (17). Furtherdataobtained bySchwimm-
beck and Oldstone (18) also demonstrated that antibodies raised to HLA B27.1 pep-
tides showed reduced or abrogated binding to peptides representing other B27 sub-1644
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types, i.e., where the aspartic acid at position 77 had been substituted. QTDRE
(residues 72-76) are common to all subtypes (except HLA B27.fwhere the aspartic
acid at position 74 is substituted with a tyrosine), and this homology or a shorter
homologous sequence (QTDR) maybesufficient to explain antibody reactivity with
other subtypes of HLA B27, since it has not been shown that one subtype is more
closely associated with AS (19).
The importance of QTDR has been confirmed by data obtained from protein
sequences in other arthritogenic bacteria. Stieglitz et al. (20) showed that a plasmid
pHS-2 from several arthritogenic Shigella strains contained a DNA sequence for an
inferred pentapeptide AQTDR, which is common to four subtypes of HLA B27
(residues 71-75). Antisera raised to an inferred decapeptideincludingAQTDR from
the plasmid sequence, and to a 24-amino acid peptide from HLA B27.1 (residues
61-84) were tested with apanel ofbacteria by Western blot. The antisera recognized
one band that was unique to arthritogenic bacteria. While the HLA B27.1 peptide
includes the homologous sequence, the entire homologous sequence is not coded
for within the Shigella plasmid, and therefore QTDRED does not appear to be the
prerequisite sequence for crossreactivity to occur. We have also demonstrated that
AS patient sera contained antibodies that bind to AQTDR (data not shown).
It hasbeen reported that as few as six or seven amino acids can form an antigenic
determinant, and as few as four or five homologous amino acids can constitute a
crossreacting antigenic determinant (18). Thepeptides we have identified as sequen-
tial epitopes are of this order of size.
The two distinct antigenic regions on HLA B27.1 that we have identified share
one positional amino acid. Residue 75, an arginine, is a surface residue on one of
the a-helices that flanks the deep groove on MHC class I molecules, which is pro-
posed tobe thebinding site for small peptides thatare presented to cytotoxic Tcells.
This arginine points away from the groove, and is predicted to be in a position to
be contacted by the TCR (11, 12). It is the overlapping residue ofepitopes I and
II, and its position and orientation on the MHC groove means that it could act as
a "post" or common residue for two autoantigenic determinants.
The other main finding ofthis study was that AS patient sera showed, on average,
significantly higher binding activity against KAKAQTDR from HLA B27.1 and
to NSRQTDR from K. pneumoniae nitrogenase than HLA B27+ and HLA B27-
control sera. Therewas a considerable overlapofindividual serum activity between
the patients and controls against these peptides. These results are consistent with
other studies that showed that not all AS seracontain antibodies to peptides derived
from HLA B27.1 (10). In our studies, some ofthe healthy control sera showed high
antibody activity tothe peptides identified as epitopes. It may bethat such antibody
activity could precede the onset ofAS or spondylarthritis in these HLA B27+ rela-
tives. Much wider testingofserafromthe normal population andfrompatientswith
other rheumatic diseases is necessary to determine the distribution and specificity
of these antibodies. The presence of antibodies that bind to HLA B27 peptides in
B27- AS patients or B27- controls theoretically has no pathogenic role in HLA B27-
relatedarthritis, within thehypothesis ofmolecular mimicry andcrossreactinganti-
genic determinants. Other HLA class I molecules may play a role in B27- AS pa-
tients. It has been shown that HLA B27- AS patients often carry HLA antigensEWING ET AL.
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from the B7 CREG group (21), and B7 and B40 are crossreactive with B27 (17).
Our own studies have shown that AS sera contain antibodies that bind to peptides
synthesized from the hypervariable regions of B7 and B40 (unpublished data).
The epitopes wehave identified on Klebsiella and HLA 1327.1 are antibody binding
sites andarethereforeB cell epitopes. Moreover, themethodology used in thisstudy
can only locate sequential epitopes. We cannot infer from the data the nature of
the Klebsiella peptides that may be presented to T cells in the initiation ofthe im-
mune response. However, the size ofthe epitopes identified on Klebsiella are consis-
tent with the projected size of linear amino acid sequences that could form T cell
epitopes, i.e., five to seven amino acids (22, 23). Further investigations using syste-
matically shortened peptides, and T cell clones are required to determine which
Klebsiella peptides can activate a proliferative T cell response and thereby initiate
acrossreactive immune response. Crossreaction ofantibacterial antibodies with an
HLA molecule, i.e., a self protein, may be sufficient to constitute a pathogenetic
mechanism, resulting in inflammatory processes and tissue damage. The presence
of antibodies bound to an HLA molecule may also interfere with HLA function.
Summary
74 overlapping peptides ofvarying lengths from Klebsiella pneumoniaenitrogenase
reductase (residues 181-199) and from the HLA B27.1 molecule (residues 65-85)
were synthesized and tested by ELISA against sera from HLA 1327+ ankylosing
spondylitis (AS) patients, and sera from HLA B27+ and HLA 1327- healthy first-
degree relatives. Antibody activity in AS sera to Klebsiella peptides of four to eight
amino acidswas maximal with the peptide NSRQTDR. Activity to HLA B27 pep-
tides was maximal with the peptide KAKAQTDR (named epitope I). These pep-
tides overlap with, but are proximal to the NH2 terminus from QTDRED, which
is homologous in HLA 1327.1 and K. pneumoniae nitrogenase reductase. A second
weaker reactive site was noted in the HLA 1327.1 peptides, proximal to the COOH
terminus from the homologous sequence, namely peptide REDLRTLL (named epi-
tope II). Little activity was seen against peptides that included the entire homolo-
gous sequence. Sera from 50ASpatients showed higher total Igactivity against pep-
tides KAKAQTDR (p <0.001) and NSRQTDR (p <0.02) than did sera from 22
1327+ and 22 1327- healthy controls. These data indicate that AS patient sera con-
tainantibodies thatbind toK. pneumoniaenitrogenasepeptides and HLA1327.1 pep-
tides, and that there are at least two epitopes on HLA 1327.1 in the cxl domain, at
the MHC groove region, that are autoantigenic in AS patients. Epitope I may be
a site for crossreactivity between HLA B27 and Klebsiella.
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Addendum: A new World Health Organization (WHO) designation has changed the nomen-
clature for HLA B27 subtypes (24). The old designation 1327.1, used in this paper, refers
to B27.5 in the new nomenclature.1646
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